Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
RGNX
Stock Latest News
Ratings
RegenXBio: Strong Financials and Undervalued Growth Potential Justify Buy Rating
8d ago
RGNX
Premium
Ratings
Optimistic Buy Rating for RegenXBio Amidst RGX-202 Program’s Promising Advancements and Strategic Safety Measures
1M ago
RGNX
Premium
Ratings
RegenXBio’s Strategic Approach and Promising Outlook Earns Buy Rating
1M ago
RGNX
Premium
Ratings
RegenXBio Positioned for Success Amidst SRPT’s Elevidys Concerns: Analyst Recommends Buy
1M ago
RGNX
Premium
The Fly
BofA expects no changes for Regenxbio regimen after competitor safety issue
1M ago
RGNX
SRPT
Premium
The Fly
Regenxbio files to sell 268,096 shares of common stock for holders
1M ago
RGNX
Premium
Ratings
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism
2M ago
RGNX
Premium
Ratings
Promising Interim Data and Accelerated Approval Pathway Drive Buy Rating for RegenXBio’s RGX-202
2M ago
RGNX
Premium
Ratings
RegenXBio: Promising Gene Therapy Developments and Strong Financial Position Support Buy Rating
2M ago
RGNX
Premium
The Fly
Regenxbio’s RGX-202 shows efficacy in Phase 1/2 Duchenne trial
2M ago
RGNX
Premium
Company Announcements
RegenXBio Holds 2025 Annual Stockholders Meeting
2M ago
8K
RGNX
Premium
Ratings
RegenXBio’s Strengthened Financial Position and Growth Prospects Drive Buy Rating
2M ago
RGNX
Premium
Company Announcements
RegenXBio Secures $250M Royalty Monetization Deal
2M ago
8K
RGNX
Premium
The Fly
Regenxbio signs strategic royalty monetization agreement for up to $250M
2M ago
RGNX
Premium
Company Announcements
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year
2M ago
RGNX
Premium
The Fly
NS Pharma announces FDA accepted BLA submission of Regenxbio for RGX-121
2M ago
RGNX
Premium
Ratings
RegenXBio’s Promising Pipeline and Financial Stability Earns Buy Rating
2M ago
RGNX
Premium
Ratings
Promising Pipeline and Strong Financials Support Buy Rating for RegenXBio
2M ago
RGNX
Premium
The Fly
Regenxbio’s BLA for RGX-121 in Hunter syndrome accepted by FDA
2M ago
RGNX
Premium
Ratings
Optimistic Buy Rating for RegenXBio Amidst Promising Gene Therapy Developments and Financial Prospects
2M ago
RGNX
Premium
Company Announcements
REGENXBIO Reports Strong Q1 2025 Financial Results
2M ago
RGNX
Premium
The Fly
Regenxbio reports Q1 EPS 12c vs. ($1.38) last year
2M ago
RGNX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
